TOP TEN perturbations for 38827_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38827_at
Selected probe(set): 209173_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38827_at (209173_at) across 6431 perturbations tested by GENEVESTIGATOR:
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):-9.262201Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |
expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) / expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary)
Relative Expression (log2-ratio):-8.490464Number of Samples:3 / 2
| Experimental | expO cervical cancer study 1 (squamous cell carcinoma, keratinizing type, NOS; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with squamous cell carcinoma, keratinizing type (NOS). | |
| Control | expO cervical cancer study 1 (mucinous adenocarcinoma, endocervical type; primary) |
| Primary tumor tissue samples obtained from the cervix uteri of patients with mucinous adenocarcinoma, endocervical type. |
expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
Relative Expression (log2-ratio):8.425624Number of Samples:6 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma. | |
| Control | expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS). |
ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-8.031755Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-8.008038Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)
Relative Expression (log2-ratio):-7.886101Number of Samples:5 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; orthotopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; orthotopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks. |
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):7.8482695Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
AGR2 overexpression study 1 / control transfected MIA PaCa-2 cell sample
Relative Expression (log2-ratio):7.537346Number of Samples:3 / 3
| Experimental | AGR2 overexpression study 1 |
| Human pancreatic cancer cell line MIA PaCa-2 stably transfected with AGR2 overexpressing pCEP4 vector. Cells were grown to 70-80% confluency before RNA extraction and maintained in DMEM with 10% FBS. | |
| Control | control transfected MIA PaCa-2 cell sample |
| Control sample of pancreatic cancer cell line MIA PaCa-2 stably transfected with empty pCEP4 vector. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Relative Expression (log2-ratio):-7.526865Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Relative Expression (log2-ratio):-7.458132Number of Samples:2 / 6
| Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
| Control | expO ovary cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma. |